Tissue factor-targeted lidamycin inhibits growth and metastasis of colon carcinoma
Qing Zhang1, Xiujun Liu, Caihong Li
1Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China ; Center for Functional Genomics and Bioinformatics, College of Life Science, Sichuan University, Chengdu, Sichuan 610064, P.R. China.
Abstract:
Colon cancer is the third most common cancer in the world. The overexpression of tissue factor (TF) in colon cancer cells makes it an ideal target for colon cancer therapy. The purpose of the present study was to develop a TF-targeting energized fusion protein, mlFVII-LDP-AE, which is composed of a mouse Factor VII light chain (mlFVII) as the targeting domain conjugated to the highly cytotoxic antibiotic lidamycin (LDM, LDP-AE) as the effector domain. The potential efficacy of mlFVII-LDP-AE for mouse colon cancer therapy was tested in a mouse colon cancer subcutaneous xenograft model and a live metastasis model in BALB/c mice. mlFVII-LDP-AE showed a tumor growth inhibition rate of 91.2% (at a dose of 0.8 mg/kg) and a tumor metastasis inhibition rate of 84.7% (at a dose of 0.6 mg/kg). The results showed that mlFVII-LDP-AE was able to effectively inhibit the growth and metastasis of mouse colon cancer. As human TF and FVII have features similar to those of mice, human FVII light chain (hlFVII)-targeted LDM (hlFVII-LDP-AE) may be expected to have therapeutic potential for human colon cancer.
Insights
A novel fusion protein targeting tissue factor (TF) effectively inhibited colon cancer growth and metastasis in mice. This development holds promise for future human colon cancer therapies.
Area of Science:
- Oncology
- Biotechnology
- Pharmacology
Background:
- Colon cancer is a leading global malignancy.
- Tissue factor (TF) overexpression in colon cancer presents a therapeutic target.
- Targeted drug delivery systems are crucial for effective cancer treatment.
Purpose of the Study:
- To develop and evaluate a novel fusion protein, mlFVII-LDP-AE, for colon cancer therapy.
- To assess the efficacy of mlFVII-LDP-AE in inhibiting tumor growth and metastasis.
- To explore the potential of TF-targeted therapy for colon cancer.
Main Methods:
- Development of a fusion protein comprising a mouse Factor VII light chain (mlFVII) targeting domain and lidamycin (LDM) effector domain (mlFVII-LDP-AE).
- Evaluation in mouse colon cancer subcutaneous xenograft and live metastasis models.
- Assessment of tumor growth inhibition and metastasis inhibition rates.
Main Results:
- mlFVII-LDP-AE demonstrated significant tumor growth inhibition (91.2% at 0.8 mg/kg).
- mlFVII-LDP-AE significantly inhibited tumor metastasis (84.7% at 0.6 mg/kg).
- The fusion protein effectively controlled both primary tumor growth and metastatic spread in preclinical models.
Conclusions:
- mlFVII-LDP-AE is a potent therapeutic agent against mouse colon cancer.
- The TF-targeting strategy shows significant potential for colon cancer treatment.
- Human FVII-targeted lidamycin (hlFVII-LDP-AE) may offer a promising therapeutic approach for human colon cancer.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...